Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14440891 | 1.00 | TRPV1 (0.54) | TRPV1PDK1PDK2PDK3PDK4 | |
| SCHEMBL14440889 | 0.90 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL5186316 | 0.90 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL5662114 | 0.88 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL5188109 | 0.86 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL5188638 | 0.81 | TRPV1 (0.53) | TRPV1PDK1PDK2PDK3PDK4 | |
| SCHEMBL4974018 | 0.79 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL14283209 | 0.79 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL4974013 | 0.79 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL4975201 | 0.79 | TRPV1 (0.58) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720826-A4 | HETEROALKYL-SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES | NEUROGEN CORP (US) | 2007-10-31 | — | — | EP | claimed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | claimed |
| EP-1720826-A2 | HETEROALKYL-SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005084368-A2 | HETEROALKYL-SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | AHR, HCAR2, HCAR1 | TRPV1 293/4885PDK1 1238/4885PDK2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.